Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.

Ewers M, Franzmeier N, Suárez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M, Trojanowski JQ, Shaw LM, Weiner MW, Haass C; Alzheimer’s Disease Neuroimaging Initiative.

Sci Transl Med. 2019 Aug 28;11(507). pii: eaav6221. doi: 10.1126/scitranslmed.aav6221.

PMID:
31462511
2.

Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool.

Jordan S, Tung N, Casanova-Acebes M, Chang C, Cantoni C, Zhang D, Wirtz TH, Naik S, Rose SA, Brocker CN, Gainullina A, Hornburg D, Horng S, Maier BB, Cravedi P, LeRoith D, Gonzalez FJ, Meissner F, Ochando J, Rahman A, Chipuk JE, Artyomov MN, Frenette PS, Piccio L, Berres ML, Gallagher EJ, Merad M.

Cell. 2019 Aug 22;178(5):1102-1114.e17. doi: 10.1016/j.cell.2019.07.050.

PMID:
31442403
3.

The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.

Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube U, Farias FG, Bradley J, Budde J, Ibanez L, Fernandez MV, Blennow K, Zetterberg H, Heslegrave A, Johansson PM, Svensson J, Nellgård B, Lleo A, Alcolea D, Clarimon J, Rami L, Molinuevo JL, Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Ewers M, Harari O, Haass C, Brett TJ, Benitez BA, Karch CM, Piccio L, Cruchaga C.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaau2291. doi: 10.1126/scitranslmed.aau2291.

PMID:
31413141
4.

T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.

Ghezzi L, Cantoni C, Cignarella F, Bollman B, Cross AH, Salter A, Galimberti D, Cella M, Piccio L.

Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092. [Epub ahead of print]

PMID:
31237799
5.

Inflammatory expression profile in peripheral blood mononuclear cells from patients with Nasu-Hakola Disease.

Galimberti D, Fenoglio C, Ghezzi L, Serpente M, Arcaro M, D'Anca M, De Riz M, Arighi A, Fumagalli GG, Pietroboni AM, Piccio L, Scarpini E.

Cytokine. 2019 Apr;116:115-119. doi: 10.1016/j.cyto.2018.12.024. Epub 2019 Jan 25.

PMID:
30690291
6.

Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.

Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque Caballero MÁ, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, Levin J, Deming Y, Piccio L, Karch CM, Cruchaga C, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurodegener. 2019 Jan 10;14(1):1. doi: 10.1186/s13024-018-0301-5.

7.

Not only cancer: the long non-coding RNA MALAT1 affects the repertoire of alternatively spliced transcripts and circular RNAs in multiple sclerosis.

Cardamone G, Paraboschi EM, Soldà G, Cantoni C, Supino D, Piccio L, Duga S, Asselta R.

Hum Mol Genet. 2019 May 1;28(9):1414-1428. doi: 10.1093/hmg/ddy438.

PMID:
30566690
8.

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.

Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Dominantly Inherited Alzheimer Network; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2018 Dec;10(12). pii: e9712. doi: 10.15252/emmm.201809712.

9.

Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota.

Cignarella F, Cantoni C, Ghezzi L, Salter A, Dorsett Y, Chen L, Phillips D, Weinstock GM, Fontana L, Cross AH, Zhou Y, Piccio L.

Cell Metab. 2018 Jun 5;27(6):1222-1235.e6. doi: 10.1016/j.cmet.2018.05.006.

10.

The Microglial Innate Immune Receptor TREM2 Is Required for Synapse Elimination and Normal Brain Connectivity.

Filipello F, Morini R, Corradini I, Zerbi V, Canzi A, Michalski B, Erreni M, Markicevic M, Starvaggi-Cucuzza C, Otero K, Piccio L, Cignarella F, Perrucci F, Tamborini M, Genua M, Rajendran L, Menna E, Vetrano S, Fahnestock M, Paolicelli RC, Matteoli M.

Immunity. 2018 May 15;48(5):979-991.e8. doi: 10.1016/j.immuni.2018.04.016. Epub 2018 May 8.

11.

Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review.

Evans E, Piccio L, Cross AH.

JAMA Neurol. 2018 Aug 1;75(8):1013-1021. doi: 10.1001/jamaneurol.2018.0611.

PMID:
29710293
12.

Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.

Warikoo N, Brunwasser SJ, Benz A, Shu HJ, Paul SM, Lewis M, Doherty J, Quirk M, Piccio L, Zorumski CF, Day GS, Mennerick S.

J Neurosci. 2018 Mar 28;38(13):3218-3229. doi: 10.1523/JNEUROSCI.3377-17.2018. Epub 2018 Feb 23.

13.

Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.

Longbrake EE, Cantoni C, Chahin S, Cignarella F, Cross AH, Piccio L.

Mult Scler. 2018 May;24(6):728-738. doi: 10.1177/1352458517707069. Epub 2017 May 8.

14.

Speaking out about gender imbalance in invited speakers improves diversity.

Klein RS, Voskuhl R, Segal BM, Dittel BN, Lane TE, Bethea JR, Carson MJ, Colton C, Rosi S, Anderson A, Piccio L, Goverman JM, Benveniste EN, Brown MA, Tiwari-Woodruff SK, Harris TH, Cross AH.

Nat Immunol. 2017 Apr 18;18(5):475-478. doi: 10.1038/ni.3707. No abstract available.

15.

Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Cantoni C, Cignarella F, Ghezzi L, Mikesell B, Bollman B, Berrien-Elliott MM, Ireland AR, Fehniger TA, Wu GF, Piccio L.

Acta Neuropathol. 2017 Jan;133(1):61-77. doi: 10.1007/s00401-016-1621-6. Epub 2016 Oct 4.

16.

A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms.

Choi IY, Piccio L, Childress P, Bollman B, Ghosh A, Brandhorst S, Suarez J, Michalsen A, Cross AH, Morgan TE, Wei M, Paul F, Bock M, Longo VD.

Cell Rep. 2016 Jun 7;15(10):2136-2146. doi: 10.1016/j.celrep.2016.05.009. Epub 2016 May 26.

17.

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.

Piccio L, Deming Y, Del-Águila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C.

Acta Neuropathol. 2016 Jun;131(6):925-33. doi: 10.1007/s00401-016-1533-5. Epub 2016 Jan 11.

18.

Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures.

Alvarez E, Piccio L, Mikesell RJ, Trinkaus K, Parks BJ, Naismith RT, Cross AH.

Mult Scler J Exp Transl Clin. 2015 Dec 24;1:2055217315623800. doi: 10.1177/2055217315623800. eCollection 2015 Jan-Dec.

19.

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.

Longbrake EE, Ramsbottom MJ, Cantoni C, Ghezzi L, Cross AH, Piccio L.

Mult Scler. 2016 Jul;22(8):1061-1070. doi: 10.1177/1352458515608961. Epub 2015 Oct 12.

20.

Detection of cortical lesions in multiple sclerosis: A new imaging approach.

Patel KR, Luo J, Alvarez E, Piccio L, Schmidt RE, Yablonskiy DA, Cross AH.

Mult Scler J Exp Transl Clin. 2015 Sep 24;1:2055217315606465. doi: 10.1177/2055217315606465. eCollection 2015 Jan-Dec.

21.

An ImmunoChip study of multiple sclerosis risk in African Americans.

Isobe N, Madireddy L, Khankhanian P, Matsushita T, Caillier SJ, Moré JM, Gourraud PA, McCauley JL, Beecham AH; International Multiple Sclerosis Genetics Consortium, Piccio L, Herbert J, Khan O, Cohen J, Stone L, Santaniello A, Cree BA, Onengut-Gumuscu S, Rich SS, Hauser SL, Sawcer S, Oksenberg JR.

Brain. 2015 Jun;138(Pt 6):1518-30. doi: 10.1093/brain/awv078. Epub 2015 Mar 28.

22.

TREM2 regulates microglial cell activation in response to demyelination in vivo.

Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM, Galimberti D, Olivecrona G, Klein RS, Cross AH, Otero K, Piccio L.

Acta Neuropathol. 2015 Mar;129(3):429-47. doi: 10.1007/s00401-015-1388-1. Epub 2015 Jan 29.

23.

Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2.

Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM.

Mol Neurodegener. 2014 Jun 3;9:20. doi: 10.1186/1750-1326-9-20.

24.

Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.

Cruz-Orengo L, Daniels BP, Dorsey D, Basak SA, Grajales-Reyes JG, McCandless EE, Piccio L, Schmidt RE, Cross AH, Crosby SD, Klein RS.

J Clin Invest. 2014 Jun;124(6):2571-84. doi: 10.1172/JCI73408. Epub 2014 May 8.

25.

Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.

Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E.

Mult Scler. 2013 Dec;19(14):1938-42. doi: 10.1177/1352458513485654.

PMID:
24277735
26.

Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1.

Angiari S, Rossi B, Piccio L, Zinselmeyer BH, Budui S, Zenaro E, Della Bianca V, Bach SD, Scarpini E, Bolomini-Vittori M, Piacentino G, Dusi S, Laudanna C, Cross AH, Miller MJ, Constantin G.

J Immunol. 2013 Dec 1;191(11):5489-500. doi: 10.4049/jimmunol.1301235. Epub 2013 Oct 30.

27.

Genetic risk variants in African Americans with multiple sclerosis.

Isobe N, Gourraud PA, Harbo HF, Caillier SJ, Santaniello A, Khankhanian P, Maiers M, Spellman S, Cereb N, Yang S, Pando MJ, Piccio L, Cross AH, De Jager PL, Cree BA, Hauser SL, Oksenberg JR.

Neurology. 2013 Jul 16;81(3):219-27. doi: 10.1212/WNL.0b013e31829bfe2f. Epub 2013 Jun 14.

28.

Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis.

Piccio L, Cantoni C, Henderson JG, Hawiger D, Ramsbottom M, Mikesell R, Ryu J, Hsieh CS, Cremasco V, Haynes W, Dong LQ, Chan L, Galimberti D, Cross AH.

Eur J Immunol. 2013 Aug;43(8):2089-100. doi: 10.1002/eji.201242836. Epub 2013 Jun 7.

29.

Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL): a new report of an Italian woman and review of the literature.

Bock V, Botturi A, Gaviani P, Lamperti E, Maccagnano C, Piccio L, Silvani A, Salmaggi A.

J Neurol Sci. 2013 Mar 15;326(1-2):115-9. doi: 10.1016/j.jns.2013.01.021. Epub 2013 Feb 9. Review.

PMID:
23399524
30.

CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions.

Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH.

Mult Scler. 2013 Aug;19(9):1204-8. doi: 10.1177/1352458512473362. Epub 2013 Jan 15.

31.

Rituximab combination therapy in relapsing multiple sclerosis.

Cross AH, Klein RS, Piccio L.

Ther Adv Neurol Disord. 2012 Nov;5(6):311-9. doi: 10.1177/1756285612461165.

32.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

33.

Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism.

Rossi B, Zenaro E, Angiari S, Ottoboni L, Bach S, Piccio L, Pietronigro EC, Scarpini E, Fusco M, Leon A, Constantin G.

J Neuroimmunol. 2011 Apr;233(1-2):97-105. doi: 10.1016/j.jneuroim.2010.12.005. Epub 2011 Jan 7.

PMID:
21216016
34.

Update on multiple sclerosis, its diagnosis and treatments.

Cross AH, Cross KA, Piccio L.

Clin Chem Lab Med. 2012 Mar 7;50(7):1203-10. doi: 10.1515/cclm-2011-0736. Review.

PMID:
22850053
35.

Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.

Klawiter EC, Piccio L, Lyons JA, Mikesell R, O'Connor KC, Cross AH.

Arch Neurol. 2010 Sep;67(9):1102-8. doi: 10.1001/archneurol.2010.197.

36.

ITAM signaling in dendritic cells controls T helper cell priming by regulating MHC class II recycling.

Graham DB, Akilesh HM, Gmyrek GB, Piccio L, Gilfillan S, Sim J, Belizaire R, Carrero JA, Wang Y, Blaufuss GS, Sandoval G, Fujikawa K, Cross AH, Russell JH, Cella M, Swat W.

Blood. 2010 Oct 28;116(17):3208-18. doi: 10.1182/blood-2009-10-250415. Epub 2010 Jul 15.

37.

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH.

Arch Neurol. 2010 Jun;67(6):707-14. doi: 10.1001/archneurol.2010.99.

38.

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH.

Neurology. 2010 Jun 8;74(23):1860-7. doi: 10.1212/WNL.0b013e3181e24373.

39.

Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males.

Fenoglio C, Scalabrini D, Esposito F, Comi C, Cavalla P, De Riz M, Martinelli V, Piccio LM, Venturelli E, Fumagalli G, Capra R, Collimedaglia L, Ghezzi A, Rodegher ME, Vercellino M, Leone M, Giordana MT, Bresolin N, Monaco F, Comi G, Scarpini E, Martinelli-Boneschi F, Galimberti D.

Genes Immun. 2010 Sep;11(6):497-503. doi: 10.1038/gene.2010.18. Epub 2010 May 13.

PMID:
20463744
40.

Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility.

Zuvich RL, McCauley JL, Oksenberg JR, Sawcer SJ, De Jager PL; International Multiple Sclerosis Genetics Consortium, Aubin C, Cross AH, Piccio L, Aggarwal NT, Evans D, Hafler DA, Compston A, Hauser SL, Pericak-Vance MA, Haines JL.

Hum Genet. 2010 Mar;127(5):525-35. doi: 10.1007/s00439-010-0789-4. Epub 2010 Jan 30.

41.

Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes.

De Riz M, Galimberti D, Fenoglio C, Piccio LM, Scalabrini D, Venturelli E, Pietroboni A, Piola M, Naismith RT, Parks BJ, Fumagalli G, Bresolin N, Cross AH, Scarpini E.

Neurosci Lett. 2010 Jan 22;469(2):234-6. doi: 10.1016/j.neulet.2009.12.002. Epub 2009 Dec 4.

42.

Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease.

Fenoglio C, Galimberti D, Cortini F, Kauwe JS, Cruchaga C, Venturelli E, Villa C, Serpente M, Scalabrini D, Mayo K, Piccio LM, Clerici F, Albani D, Mariani C, Forloni G, Bresolin N, Goate AM, Scarpini E.

J Alzheimers Dis. 2009;18(3):603-12. doi: 10.3233/JAD-2009-1170.

43.

Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.

De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S; International MS Genetics Consortium, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR.

Nat Genet. 2009 Jul;41(7):776-82. doi: 10.1038/ng.401. Epub 2009 Jun 14.

44.

Candidate gene analysis of selectin cluster in patients with multiple sclerosis.

Fenoglio C, Scalabrini D, Piccio L, De Riz M, Venturelli E, Cortini F, Villa C, Serpente M, Parks B, Rinker J, Cross AH, Bresolin N, Scarpini E, Galimberti D.

J Neurol. 2009 May;256(5):832-3. doi: 10.1007/s00415-009-5016-7. Epub 2009 Feb 25.

PMID:
19240957
45.

Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation.

Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, Rinker J 2nd, Naismith RT, Panina-Bordignon P, Passini N, Galimberti D, Scarpini E, Colonna M, Cross AH.

Brain. 2008 Nov;131(Pt 11):3081-91. doi: 10.1093/brain/awn217. Epub 2008 Sep 12.

46.

Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis.

Piccio L, Stark JL, Cross AH.

J Leukoc Biol. 2008 Oct;84(4):940-8. doi: 10.1189/jlb.0208133. Epub 2008 Aug 4.

47.

Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.

McCandless EE, Piccio L, Woerner BM, Schmidt RE, Rubin JB, Cross AH, Klein RS.

Am J Pathol. 2008 Mar;172(3):799-808. doi: 10.2353/ajpath.2008.070918. Epub 2008 Feb 14.

48.

Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis.

Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH, Colonna M, Panina-Bordignon P.

Eur J Immunol. 2007 May;37(5):1290-301.

49.

Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration.

Fenoglio C, Galimberti D, Piccio L, Scalabrini D, Panina P, Buonsanti C, Venturelli E, Lovati C, Forloni G, Mariani C, Bresolin N, Scarpini E.

Neurosci Lett. 2007 Jan 10;411(2):133-7. Epub 2006 Nov 7.

PMID:
17088018
50.

Cutting edge: TREM-2 attenuates macrophage activation.

Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M.

J Immunol. 2006 Sep 15;177(6):3520-4.

Supplemental Content

Loading ...
Support Center